Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions

CONCLUSION: Rates of bladder cancer progression and disseminated BCG complications 5-years after BCG therapy were similar regardless of immunomodulation status. These findings suggest that BCG intravesical therapy can be offered to immunomodulated patients with high-risk NMIBC although theoretical infectious complication risks remain.PMID:37852817 | DOI:10.1016/j.urolonc.2023.09.010

Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Adri M Durant Mouneeb M Choudry Grace Madura Lanyu Mi Kassem S Faraj Mark D Tyson Source Type: research